Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02930941 · ClinicalTrials.gov registry record · Phase 4
Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department
A Phase 4 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT02930941 is a Phase 4 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 35 participants.
The verdict
NCT02930941, a Phase 4 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
It is estimated that epistaxis results in 4.5 million emergency department visits per year throughout the United States. Due to the adverse effects of standard treatment options for epistaxis, tranexamic acid (TXA) may be considered an attractive option. In previous studies, when used with nasal packing, TXA showed faster time to control of bleeding. The goal of this study is to determine the efficacy and safety of topical intranasal TXA applied via atomizer for patients with epistaxis who present to the emergency department.
Interventions
- DRUG Tranexamic Acid
- DRUG 0.9% Sodium Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-02 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02930941
The ClinicalTrials.gov registry entry for NCT02930941 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tranexamic Acid is the first listed.
NCT02930941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02930941 about?
NCT02930941 is a clinical study titled "Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department". It is estimated that epistaxis results in 4.5 million emergency department visits per year throughout the United States. Due to the adverse effects of standard treatment options for epistaxis, tranexamic acid (TXA) may be considered an attractive option. In previous studies, when used with nasal pac...
What is the current status of trial NCT02930941?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2016-02. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT02930941?
The interventions under investigation include: Tranexamic Acid (DRUG), 0.9% Sodium Chloride (DRUG).
Who is sponsoring clinical trial NCT02930941?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.